drugset / Trial / NCT00206219

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

NCT00206219

Phase 3 Completed 477 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.

Timeline

Start
2003-11
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule 250 mg
Subject Gefitinib Small molecule 500 mg
Subject Methotrexate Small molecule